Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IL-17 mediates resistance to anti-VEGF therapy

Interleukin-17 (IL-17) released in the tumor microenvironment in response to drugs blocking vascular endothelial growth factor (VEGF) triggers stromal-derived inflammatory and VEGF-independent angiogenic programs that induce the drug refractoriness found in cancers resistant to anti-angiogenic therapy (pages 1114–1123).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1: Stroma-mediated development of anti-VEGF resistance.

Marina Corral Spence


  1. Carmeliet, P. & Jain, R.K. Nature 473, 298–307 (2011).

    Article  CAS  Google Scholar 

  2. Ferrara, N. & Kerbel, R.S. Nature 438, 967–974 (2005).

    Article  CAS  Google Scholar 

  3. Kieran, M.W., Kalluri, R. & Cho, Y.J. Cold Spring Harb. Perspect. Med. 2, a006593 (2012).

    Article  Google Scholar 

  4. Leek, R.D., Harris, A.L. & Lewis, C.E. J. Leukoc. Biol. 56, 423–435 (1994).

    Article  CAS  Google Scholar 

  5. Holash, J. et al. Science 284, 1994–1998 (1999).

    Article  CAS  Google Scholar 

  6. Chung, A.S. et al. Nat. Med. 19, 1114–1123 (2013).

    Article  CAS  Google Scholar 

  7. McMillin, D.W., Negri, J.M. & Mitsiades, C.S. Nat. Rev. Drug Discov. 12, 217–228 (2013).

    Article  CAS  Google Scholar 

  8. De Palma, M. & Lewis, C. Cancer Cell 23 Issue 3, 277–286 (2013).

    Article  CAS  Google Scholar 

  9. Du, R. et al. Cancer Cell 13, 206–220 (2008).

    Article  CAS  Google Scholar 

  10. Bergers, G. & Song, S. Neuro Oncol. 7, 452–464 (2005).

    Article  CAS  Google Scholar 

  11. De Palma, M. et al. Cancer Cell 8, 211–226 (2005).

    Article  CAS  Google Scholar 

  12. Gabrilovich, D.I., Ostrand-Rosenberg, S. & Bronte, V. Nat. Rev. Immunol. 12, 253–268 (2012).

    Article  CAS  Google Scholar 

  13. Crawford, Y. et al. Cancer Cell 15, 21–34 (2009).

    Article  CAS  Google Scholar 

  14. Shojaei, F. et al. Nat. Biotechnol. 25, 911–920 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Thorsten Hagemann.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Maniati, E., Hagemann, T. IL-17 mediates resistance to anti-VEGF therapy. Nat Med 19, 1092–1094 (2013).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer